ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 136 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2021. The put-call ratio across all filers is 1.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,874,148 | +19.2% | 5,994,029 | +69.0% | 0.00% | +50.0% |
| Q2 2023 | $4,929,949 | +74157.4% | 3,546,726 | -15.1% | 0.00% | -33.3% |
| Q1 2023 | $6,639 | -56.9% | 4,175,274 | +68.7% | 0.00% | -66.7% |
| Q4 2022 | $15,415 | -99.9% | 2,474,309 | +43.6% | 0.01% | +28.6% |
| Q3 2022 | $11,545,000 | -32.9% | 1,723,175 | -36.3% | 0.01% | -36.4% |
| Q2 2022 | $17,212,000 | +197.2% | 2,706,290 | +116.8% | 0.01% | +266.7% |
| Q1 2022 | $5,792,000 | +246.4% | 1,248,338 | +273.3% | 0.00% | +200.0% |
| Q4 2021 | $1,672,000 | -70.3% | 334,430 | -28.4% | 0.00% | -66.7% |
| Q3 2021 | $5,631,000 | -16.0% | 467,298 | +47.4% | 0.00% | -25.0% |
| Q2 2021 | $6,703,000 | -35.9% | 316,933 | -14.9% | 0.00% | -42.9% |
| Q1 2021 | $10,452,000 | +189.1% | 372,614 | +168.0% | 0.01% | +133.3% |
| Q4 2020 | $3,615,000 | -69.2% | 139,041 | -56.0% | 0.00% | -78.6% |
| Q3 2020 | $11,751,000 | -63.6% | 316,133 | -49.8% | 0.01% | -68.2% |
| Q2 2020 | $32,281,000 | +1102.3% | 629,139 | +638.7% | 0.04% | +633.3% |
| Q1 2020 | $2,685,000 | -82.6% | 85,165 | -67.0% | 0.01% | -68.4% |
| Q4 2019 | $15,394,000 | +412.3% | 258,151 | +214.9% | 0.02% | +280.0% |
| Q3 2019 | $3,005,000 | -71.1% | 81,987 | -63.3% | 0.01% | -66.7% |
| Q2 2019 | $10,406,000 | -27.6% | 223,684 | -37.5% | 0.02% | -31.8% |
| Q1 2019 | $14,381,000 | +278.7% | 358,173 | +334.0% | 0.02% | +266.7% |
| Q4 2018 | $3,797,000 | +168.0% | 82,536 | +158.4% | 0.01% | +200.0% |
| Q3 2018 | $1,417,000 | -58.3% | 31,937 | -63.2% | 0.00% | -50.0% |
| Q2 2018 | $3,402,000 | -65.0% | 86,817 | -35.5% | 0.00% | -69.2% |
| Q1 2018 | $9,729,000 | -61.9% | 134,503 | -65.3% | 0.01% | -62.9% |
| Q4 2017 | $25,542,000 | +1427.6% | 387,947 | +1062.7% | 0.04% | +1066.7% |
| Q3 2017 | $1,672,000 | +450.0% | 33,367 | +407.9% | 0.00% | +200.0% |
| Q2 2017 | $304,000 | -72.9% | 6,570 | -79.3% | 0.00% | -50.0% |
| Q1 2017 | $1,121,000 | -44.1% | 31,761 | -80.2% | 0.00% | -50.0% |
| Q4 2016 | $2,006,000 | +94.2% | 160,195 | +114.7% | 0.00% | +100.0% |
| Q3 2016 | $1,033,000 | -45.3% | 74,598 | -33.1% | 0.00% | -60.0% |
| Q1 2016 | $1,887,000 | -12.3% | 111,577 | +15.5% | 0.01% | 0.0% |
| Q4 2015 | $2,151,000 | -60.3% | 96,609 | +65.3% | 0.01% | -50.0% |
| Q1 2015 | $5,412,000 | +1411.7% | 58,444 | +559.5% | 0.01% | +900.0% |
| Q4 2014 | $358,000 | -80.5% | 8,862 | -88.2% | 0.00% | -80.0% |
| Q3 2014 | $1,835,000 | +48.2% | 75,036 | -4.0% | 0.01% | +66.7% |
| Q2 2014 | $1,238,000 | +4.7% | 78,181 | 0.0% | 0.00% | 0.0% |
| Q1 2014 | $1,182,000 | +43.4% | 78,181 | +30.3% | 0.00% | 0.0% |
| Q4 2013 | $824,000 | – | 60,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |